Literature DB >> 2715933

Pharmacodynamic modeling of digoxin-induced bradycardia.

S J Vetticaden1, W H Barr, T B Allison.   

Abstract

Digoxin-induced bradycardia in dogs was used to evaluate several pharmacodynamic models. Digoxin plasma concentrations and response were monitored in beagle dogs administered either 0.05 or 0.025 mg/kg of digoxin iv as an infusion over 5 min. The models investigated were the linking model, the linear model, the effect compartment model, and the inhibitory model. Regression procedures for investigating the effect compartment model were conducted with Emax (the maximal response, where response was the percentage decrease in heart rate) as a variable with an upper bound of 100%, with a constant value of 100%, or alternately with a constant value equal to the maximal observed response. Based on statistical criteria the effect model using Emax as a variable was found to be the best model for describing digoxin-induced bradycardia. For the effect compartment model, CPss(50) (concentration at steady state that will produce 50% of the maximal response) ranged from 3.8-9.8 ng/ml; delta (exponent describing the steepness of the concentration-response relationship) ranged from 0.6-7.1. The implication of these models in understanding concentration-effect relationships are discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2715933     DOI: 10.1007/BF01059089

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  19 in total

Review 1.  The pharmacokinetic bases of biological response quantification in toxicology, pharmacology and pharmacodynamics.

Authors:  E R Garrett
Journal:  Prog Drug Res       Date:  1977

2.  Pharmacokinetics of digoxin: relationship between response intensity and predicted compartmental drug levels in man.

Authors:  W G Kramer; A J Kolibash; R P Lewis; M S Bathala; J A Visconti; R H Reuning
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

3.  Rational intravenous doses of theophylline.

Authors:  P A Mitenko; R I Ogilvie
Journal:  N Engl J Med       Date:  1973-09-20       Impact factor: 91.245

4.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

Review 5.  Pharmacokinetic and pharmacodynamic modeling in vivo.

Authors:  N H Holford; L B Sheiner
Journal:  Crit Rev Bioeng       Date:  1981

6.  Modeling of drug response in individual subjects.

Authors:  A W Kelman; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1980-04

7.  Pharmacokinetics and pharmacodynamics of d-tubocurarine during nitrous oxide-narcotic and halothane anesthesia in man.

Authors:  D R Stanski; J Ham; R D Miller; L B Sheiner
Journal:  Anesthesiology       Date:  1979-09       Impact factor: 7.892

8.  Relationship between concentration and anticoagulant effect of heparin in plasma of normal subjects: magnitude and predictability of interindividual differences.

Authors:  L R Whitfield; G Levy
Journal:  Clin Pharmacol Ther       Date:  1980-10       Impact factor: 6.875

9.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

Authors:  L B Sheiner; D R Stanski; S Vozeh; R D Miller; J Ham
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

10.  Pharmacodynamic modeling of thiopental anesthesia.

Authors:  D R Stanski; R J Hudson; T D Homer; L J Saidman; E Meathe
Journal:  J Pharmacokinet Biopharm       Date:  1984-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.